Redmile Group as of Dec. 31, 2019
Portfolio Holdings for Redmile Group
Redmile Group holds 64 positions in its portfolio as reported in the December 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Deciphera Pharmaceuticals | 7.0 | $293M | 4.7M | 62.24 | |
| Allakos | 6.9 | $289M | 3.0M | 95.36 | |
| Amicus Therapeutics (FOLD) | 5.9 | $246M | 25M | 9.74 | |
| Fate Therapeutics (FATE) | 5.2 | $220M | 11M | 19.57 | |
| Epizyme | 5.2 | $215M | 8.7M | 24.60 | |
| Argenx Se (ARGX) | 4.4 | $185M | 1.2M | 160.52 | |
| Uniqure Nv (QURE) | 4.4 | $183M | 2.6M | 71.66 | |
| Principia Biopharma | 3.6 | $149M | 2.7M | 54.78 | |
| Biogen Idec (BIIB) | 3.2 | $136M | 458k | 296.73 | |
| Igm Biosciences (IGMS) | 2.9 | $120M | 3.1M | 38.16 | |
| Bristol Myers Squibb (BMY) | 2.8 | $116M | 1.8M | 64.19 | |
| Nevro (NVRO) | 2.6 | $110M | 939k | 117.54 | |
| Forty Seven | 2.6 | $109M | 2.8M | 39.37 | |
| Aprea Therapeutics | 2.5 | $104M | 2.3M | 45.89 | |
| Regenxbio Inc equity us cm (RGNX) | 2.5 | $103M | 2.5M | 40.97 | |
| Centene Corporation (CNC) | 2.3 | $98M | 1.6M | 62.87 | |
| Tricida | 1.9 | $80M | 2.1M | 37.74 | |
| Atara Biotherapeutics | 1.8 | $77M | 4.6M | 16.47 | |
| ImmunoGen | 1.8 | $75M | 15M | 5.11 | |
| Boston Scientific Corporation (BSX) | 1.8 | $74M | 1.6M | 45.22 | |
| Tandem Diabetes Care (TNDM) | 1.7 | $70M | 1.2M | 59.61 | |
| Momenta Pharmaceuticals | 1.5 | $64M | 3.2M | 19.73 | |
| Krystal Biotech (KRYS) | 1.4 | $60M | 1.1M | 55.38 | |
| UnitedHealth (UNH) | 1.4 | $60M | 203k | 293.98 | |
| Novartis (NVS) | 1.3 | $54M | 573k | 94.69 | |
| Pra Health Sciences | 1.2 | $50M | 450k | 111.15 | |
| Axonics Modulation Technolog (AXNX) | 1.0 | $43M | 1.5M | 27.71 | |
| Hca Holdings (HCA) | 1.0 | $42M | 285k | 147.81 | |
| Ptc Therapeutics I (PTCT) | 1.0 | $41M | 860k | 48.03 | |
| Eidos Therapeutics | 1.0 | $40M | 701k | 57.39 | |
| Replimune Group (REPL) | 0.9 | $40M | 2.8M | 14.35 | |
| Scholar Rock Hldg Corp (SRRK) | 0.9 | $39M | 2.9M | 13.18 | |
| Audentes Therapeutics | 0.9 | $38M | 639k | 59.84 | |
| Anthem (ELV) | 0.7 | $30M | 101k | 302.03 | |
| Guardant Health (GH) | 0.7 | $31M | 390k | 78.14 | |
| Amedisys (AMED) | 0.7 | $30M | 181k | 166.92 | |
| Ardelyx (ARDX) | 0.7 | $30M | 4.0M | 7.50 | |
| Cigna Corp (CI) | 0.7 | $30M | 148k | 204.49 | |
| Stoke Therapeutics (STOK) | 0.7 | $29M | 1.0M | 28.32 | |
| Gritstone Oncology Ord (GRTSQ) | 0.7 | $28M | 3.1M | 8.97 | |
| Wave Life Sciences (WVE) | 0.6 | $27M | 3.3M | 8.02 | |
| Akero Therapeutics (AKRO) | 0.6 | $26M | 1.2M | 22.19 | |
| Odonate Therapeutics Ord | 0.6 | $26M | 790k | 32.45 | |
| Tcr2 Therapeutics Inc cs | 0.6 | $26M | 1.8M | 14.28 | |
| Shockwave Med | 0.6 | $25M | 568k | 43.92 | |
| Neoleukin Therapeutics | 0.6 | $24M | 1.9M | 12.32 | |
| Hookipa Pharma Inc equity | 0.6 | $23M | 1.9M | 12.23 | |
| Xeris Pharmaceuticals | 0.5 | $21M | 3.0M | 7.05 | |
| Genmab A/s -sp (GMAB) | 0.5 | $21M | 937k | 22.33 | |
| Cabaletta Bio (CABA) | 0.5 | $20M | 1.4M | 13.97 | |
| Atreca Inc Cl A (BCEL) | 0.4 | $18M | 1.1M | 15.47 | |
| Stereotaxis (STXS) | 0.4 | $17M | 3.2M | 5.29 | |
| G1 Therapeutics | 0.4 | $16M | 614k | 26.43 | |
| Cryoport Inc Com Par $0 001 (CYRX) | 0.3 | $14M | 842k | 16.46 | |
| Adaptive Biotechnologies Cor (ADPT) | 0.3 | $13M | 426k | 29.92 | |
| Vapotherm | 0.3 | $12M | 960k | 12.16 | |
| Glycomimetics | 0.2 | $7.1M | 1.3M | 5.29 | |
| Biontech Se (BNTX) | 0.1 | $5.9M | 174k | 33.88 | |
| Cymabay Therapeutics | 0.1 | $5.5M | 2.8M | 1.96 | |
| Gossamer Bio (GOSS) | 0.1 | $4.1M | 260k | 15.63 | |
| Syros Pharmaceuticals | 0.0 | $1.5M | 212k | 6.91 | |
| Ovid Therapeutics (OVID) | 0.0 | $506k | 122k | 4.15 | |
| Castlight Health | 0.0 | $14k | 10k | 1.37 | |
| Endologix | 0.0 | $124k | 79k | 1.57 |
